You just read:

FDA Grants Priority Review for Daiichi Sankyo's New Drug Application for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

News provided by

Daiichi Sankyo Company, Limited

Nov 21, 2018, 10:00 ET